Toggle Side Panel
Close search

Eiger BioPharmaceuticals Discontinues Ubenimex for PAH Clinical Trial

  • Research & Development

    Eiger BioPharmaceuticals Discontinues Ubenimex for PAH Clinical Trial

    Posted by Community Member on August 23, 2018 at 6:24 pm

    Eiger Biopharmaceuticals has discontinued development Ubenimex for the treatment of pulmonary arterial hypertension (PAH). Read more here.

    What are your thoughts on this news?

    replied 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .